# Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

> **NCT05197842** · PHASE1,PHASE2 · COMPLETED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 93 (actual)

## Conditions studied

- ANCA-associated Vasculitis

## Interventions

- **DRUG:** BDB-001 injection
- **DRUG:** Cyclophosphamide
- **DRUG:** Glucocorticoids

## Key facts

- **NCT ID:** NCT05197842
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-22
- **Primary completion:** 2025-03-19
- **Final completion:** 2025-03-19
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05197842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05197842, "Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05197842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*